Your browser doesn't support javascript.
Pulmonary adverse drug event data in hypertension with implications on COVID-19 morbidity.
Jaberi-Douraki, Majid; Meyer, Emma; Riviere, Jim; Gedara, Nuwan Indika Millagaha; Kawakami, Jessica; Wyckoff, Gerald J; Xu, Xuan.
  • Jaberi-Douraki M; 1DATA Consortium, Manhattan, USA. jaberi@k-state.edu.
  • Meyer E; Kansas State University Olathe, Olathe, KS, 66061-1304, USA. jaberi@k-state.edu.
  • Riviere J; Department of Mathematics, Kansas State University, Manhattan, USA. jaberi@k-state.edu.
  • Gedara NIM; 1DATA Consortium, Manhattan, USA.
  • Kawakami J; Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, USA.
  • Wyckoff GJ; 1DATA Consortium, Manhattan, USA.
  • Xu X; Kansas State University, Manhattan, USA.
Sci Rep ; 11(1): 13349, 2021 06 25.
Article in English | MEDLINE | ID: covidwho-1281740
ABSTRACT
Hypertension is a recognized comorbidity for COVID-19. The association of antihypertensive medications with outcomes in patients with hypertension is not fully described. However, angiotensin-converting enzyme 2 (ACE2), responsible for host entry of the novel coronavirus (SARS-CoV-2) leading to COVID-19, is postulated to be upregulated in patients taking angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs). Here, we evaluated the occurrence of pulmonary adverse drug events (ADEs) in patients with hypertension receiving ACEIs/ARBs to determine if disparities exist between individual drugs within the respective classes using data from the FDA Spontaneous Reporting Systems. For this purpose, we proposed the proportional reporting ratio to provide a statistical summary for the commonality of an ADE for a specific drug as compared to the entire database for drugs in the same or other classes. In addition, a statistical procedure, multiple logistic regression analysis, was employed to correct hidden confounders when causative covariates are underreported or untrusted to correct analyses of drug-ADE combinations. To date, analyses have been focused on drug classes rather than individual drugs which may have different ADE profiles depending on the underlying diseases present. A retrospective analysis of thirteen pulmonary ADEs showed significant differences associated with quinapril and trandolapril, compared to other ACEIs and ARBs. Specifically, quinapril and trandolapril were found to have a statistically significantly higher incidence of pulmonary ADEs compared with other ACEIs as well as ARBs (P < 0.0001) for group comparison (i.e., ACEIs vs. ARBs vs. quinapril vs. trandolapril) and (P ≤ 0.0007) for pairwise comparison (i.e., ACEIs vs. quinapril, ACEIs vs. trandolapril, ARBs vs. quinapril, or ARBs vs. trandolapril). This study suggests that specific members of the ACEI antihypertensive class (quinapril and trandolapril) have a significantly higher cluster of pulmonary ADEs.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Angiotensin-Converting Enzyme Inhibitors / Angiotensin Receptor Antagonists / Quinapril / COVID-19 / COVID-19 Drug Treatment / Hypertension / Indoles / Antihypertensive Agents Type of study: Experimental Studies / Observational study Limits: Humans Language: English Journal: Sci Rep Year: 2021 Document Type: Article Affiliation country: S41598-021-92734-7

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Angiotensin-Converting Enzyme Inhibitors / Angiotensin Receptor Antagonists / Quinapril / COVID-19 / COVID-19 Drug Treatment / Hypertension / Indoles / Antihypertensive Agents Type of study: Experimental Studies / Observational study Limits: Humans Language: English Journal: Sci Rep Year: 2021 Document Type: Article Affiliation country: S41598-021-92734-7